Janux Therapeutics (JANX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.55
- EPS estimate
- −$0.47
- EPS surprise
- −16.45%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $272,727.00
- Reported
- Aug 7, 2025
Janux Therapeutics' most recent results in the table are for Q2 2025, reported on August 7, 2025. The company posted a loss of $0.55 per share, wider than the −$0.47 estimate by 16.45%. Analysts expected revenue of about $0.27 million, but none was reported. Compared with Q2 2024, the loss per share widened from $0.11, when the company recorded $8.9 million in revenue, the highest quarter in the table.
Janux has reported a loss in all 17 quarters shown. Annual losses narrowed slightly from $1.52 per share in 2022 to $1.34 in 2023 and $1.28 in 2024. Quarterly revenue has been small and irregular, ranging from $0.44 million to $8.9 million in the quarters where it was reported, with none recorded from Q4 2024 on. Q2 2025's loss was the widest since Q2 2021. Over the 17 quarters in the table, Janux beat the EPS estimate 10 times, missed six times and matched once, with six beats in the last eight quarters.
The table has not been updated since the Q2 2025 report. In earlier years, Janux reported Q3 results between November 6 and November 10. Later quarters will show whether losses keep widening and whether revenue returns.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$0.47 | −$0.55 | −16.45% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.38 | −$0.38 | +0.55% | $0.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.46 | −$0.36 | +21.86% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.33 | −$0.51 | −55.82% | $439,000.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.31 | −$0.11 | +64.60% | $8.9M | SEC |
| Q1 2024 | May 8, 2024 | −$0.33 | −$0.30 | +9.45% | $1.3M | SEC |
| Q4 2023 | Mar 8, 2024 | −$0.42 | −$0.25 | +39.79% | $2.5M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.47 | −$0.25 | +46.81% | $2.5M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.50 | −$0.42 | +16.33% | $1.1M | SEC |
| Q1 2023 | May 9, 2023 | −$0.49 | −$0.42 | +13.58% | $2.0M | SEC |
| Q4 2022 | Mar 10, 2023 | −$0.48 | −$0.39 | +18.95% | $2.8M | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.47 | −$0.40 | +14.44% | $1.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.32 | −$0.41 | −29.46% | $2.4M | SEC |
| Q1 2022 | May 10, 2022 | −$0.32 | −$0.32 | +0.00% | $1.6M | SEC |
| Q4 2021 | Mar 18, 2022 | −$0.27 | −$0.33 | −22.22% | $1.6M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.18 | −$0.26 | −47.14% | $1.2M | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.14 | −$0.62 | −342.86% | $491,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Janux Therapeutics (JANX) last report earnings?
Janux Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did JANX beat earnings estimates?
No. Janux Therapeutics reported EPS of −$0.55 for Q2 2025 against a −$0.47 estimate — a 16.45% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.